December 5, 2016 / 12:22 PM / in a year

BRIEF-Sorrento Therapeutics' study for ztlido meets primary endpoint

Dec 5 (Reuters) - Sorrento Therapeutics Inc :

* Sorrento Therapeutics Inc - study for lead investigational product, ztlido has met a primary endpoint

* Sorrento subsidiary, Scilex Pharmaceuticals announces key endpoints met in pivotal bioequivalence clinical study for its lead product, ztlido

* Scilex Pharmaceuticals Inc - full data will be resubmitted to FDA as part of 505(B)(2) new drug application (NDA) in mid-2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below